Acutaas Chemicals Merger & Restructuring Worth ₹0.01 Cr

Acutaas Chemicals Earnings Call Transcript: Key Takeaways

Acutaas reports high-growth Q2 fueled by pharma intermediates and CDMO scaling, despite commodity chemical phase-outs.

Call

Guides 100% growth

Acutaas Chemicals Investor Presentation: Key Takeaways

Q2 FY27 revenue ₹4,369 Mn (+42.7% YoY), EBITDA ₹1,760 Mn (+84.6%, 40.3% margin), PAT ₹1,231 Mn (+71.4%). FY27 revenue guidance raised; South Korea semiconductor-chemicals facility inaugurated.

Call

Guides 30% growth

Acutaas Chemicals Results Update

Q2 FY27 revenue rose 42.7% YoY to ₹4,369 mn; PAT up 71.4% to ₹1,231 mn. Guidance raised to 30% revenue growth and 38-40% EBITDA margin.

Acutaas Chemicals Q2 FY27 Results: Net Profit ₹123.1 Cr, Up 71.2% YoY

Acutaas Chemicals Ltd reported revenue from operations of ₹436.9 Cr (+42.7% YoY) and net profit of ₹123.1 Cr (+71.2% YoY) for Q2 FY27.

Key figure

Net profit ₹123.1 Cr · +71.2% YoY

Acutaas Chemicals Financial Results

Acutaas Chemicals' board approved Q2 and half-year FY2027 unaudited results. The board meeting closed with no other material transaction disclosed.

Acutaas Chemicals Board Meeting Date

Acutaas Chemicals scheduled its board meeting for October 27, 2026, to approve Q2 and H1 FY27 unaudited results. No financial figures or decisions are reported, only the meeting date and agenda.

Quint Digital Merger & Restructuring

Quint Digital's board approved a Rule 10b5-1 trading plan and the incorporation of a wholly owned overseas subsidiary. No investment amount was disclosed.

Hexaware Technologies Merger & Restructuring

Hexaware Technologies approved a slump sale of its step-down subsidiary Tech SMC Square India to Tech SMC Squared (GCC) India, a related-party deal. Consideration is cash, yet to be set by a registered valuer.

Execution

Expected completion by 30 June 2027; agreement date stated as 1 December 2026

Emkay Global Financial Services Merger & Restructuring Worth ₹2.75 Cr

Emkay Global agreed to sell its Wealth Management Business to a step-down subsidiary, Emkay Wealth Advisory, for Rs. 2.75 Crore cash. Completion is expected by 26 January 2027.

Value

₹2.75 Cr

Execution

Completion expected by 26 January 2027

TVS Holdings Merger & Restructuring

TVS Holdings forwarded TVS Motor's board outcome of October 28, 2026 approving acquisition of Harita ARC and a composite scheme of amalgamation and demerger. The scheme is subject to stock exchange, SEBI, NCLT and shareholder approvals.

Emkay Global Financial Services Merger & Restructuring Worth ₹30 Cr

Emkay Global approved transferring two subsidiaries to new subsidiary ECPL and slump-selling its wealth business. Up to Rs.30 Crore rights investment in ECPL was also approved.

Value

₹30.00 Cr

Execution

Divestment completion expected within 90 days of SPA execution, subject to regulatory approvals

Fortis Healthcare Merger & Restructuring Worth ₹277 Cr

Fortis subsidiary International Hospital acquired Suguna Ramaiah Hospitals' business, operations, land and building for Rs 277 Crore cash. The deal was consummated today, strengthening Bengaluru presence.

Value

₹277.0 Cr